ArticleMolecular biology reports2026
Lactobacillus brevis cell-free supernatant attenuates inflammation-associated gene expression and differentially modulates host defense-associated genes in DSS-stimulated HT-29 cells.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDysregulated Toll-like receptor (TLR) signaling in intestinal epithelial cells contributes to persistent mucosal inflammation in inflammatory bowel disease (IBD). Although Lactobacillus brevis has demonstrated anti-inflammatory potential, the transcriptional effects of its secreted metabolites on inflammatory and host defense-associated components of epithelial innate immune signaling remain insufficiently characterized. This study investigated the effects of L. brevis cell-free supernatant (CFS) on TLR-associated gene expression in DSS-stimulated HT-29 cells.
methods1% DSS stimulated HT-29 human intestinal epithelial cells (inflammatory epithelial model) were treated with 50% L. brevis CFS (48 h) following viability assessment using MTT assay. Transcriptional profiling of 84 key genes involved in the TLR signaling pathway was performed using the RT² Profiler™ PCR Array. Differential gene expression was analyzed using the ΔΔCt method, followed by pathway-level mapping of the MyD88- and TRIF-dependent branches. Raw p-values were adjusted for multiple comparisons using the Benjamini-Hochberg FDR procedure.
resultsTreatment with L. brevis CFS was associated with significant downregulation of multiple inflammation-associated genes, including TLR2, TLR4, MYD88, TIRAP, IRAK1, IRAK4, MAP3K7, NFKB1, IL1A, IL1B, IL6, IL12A, CCL2, and PTGS2. Host defense-associated genes exhibited a non-uniform transcriptional response. Components of the TRIF-dependent antiviral axis, including TLR3, TICAM1, TBK1, IRF3, and CXCL10, were downregulated, whereas TLR1, TLR10, TICAM2, and BTK were upregulated, and several other immune-response genes showed no significant change. These findings indicate differential modulation of TLR-associated transcription rather than uniform suppression of all examined immune-related genes.
conclusionsL. brevis CFS attenuated the expression of multiple inflammation-associated genes and differentially modulated host defense-associated genes in DSS-stimulated HT-29 cells. This non-uniform transcriptional pattern indicates selective modulation of the TLR-associated gene network rather than indiscriminate suppression of all examined immune-related genes.
Indexed as
Identifiers
42900277What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.